OC
LXRX icon

Oppenheimer & Co’s Lexicon Pharmaceuticals LXRX Stock Holding History

Oppenheimer & Co’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.7K Hold
23,500
– – ﹤0.01% 1671
2025
Q4 		$27K Hold
23,500
– – ﹤0.01% 1520
2025
Q3 		$31.7K Hold
23,500
– – ﹤0.01% 1636
2025
Q2 		$22.2K Buy
23,500
+3,400
+17% +$2.2K ﹤0.01% 1593
2025
Q1 		$9.26K Buy
+20,100
New +$12.7K ﹤0.01% 1562
2024
Q1 		– Sell
-24,500
Closed -$37.5K – 1483
2023
Q4 		$37.5K Buy
+24,500
New +$29.1K ﹤0.01% 1360

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Oppenheimer & Co's LXRX Position: Q1 2026 in Review

Oppenheimer & Co held its Lexicon Pharmaceuticals (LXRX) position steady in Q1 2026 at 23,500 shares worth $36.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1671.

Oppenheimer & Co first reported a position in LXRX in Q4 2023 and has held it in 6 quarters since. The position peaked at $37.5K in Q4 2023. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Oppenheimer & Co held 23,500 shares of Lexicon Pharmaceuticals worth $36.7K as of Q1 2026.
  • Oppenheimer & Co left its Lexicon Pharmaceuticals share count unchanged in Q1 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Oppenheimer & Co's portfolio in Q1 2026, its #1671 holding.
  • Oppenheimer & Co first reported a position in Lexicon Pharmaceuticals in Q4 2023 and has held it in 6 quarters since.
  • Oppenheimer & Co's Lexicon Pharmaceuticals position peaked at $37.5K in Q4 2023.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.